Fundraising FoxBlueWillow Biologics
Ann Arbor, US · 1 known investors
Find your way into BlueWillow Biologics
Sign up to see every warm intro you have to BlueWillow Biologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BlueWillow Biologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BlueWillow Biologics develops an intranasal vaccine delivery platform using novel oil-in-water emulsion technology to address pandemic preparedness, infectious diseases, and food allergies. The company is a clinical-stage biotech firm with proprietary technology originally discovered at the University of Michigan.
Founders & leadership
CC
GA
George AridaChief Financial and Operating OfficerGeorge Arida is Chief Financial and Operating Officer of BlueWillow Biologics, a clinical-stage biotech firm developing an intranasal vaccine delivery platform. He has held roles as an investor, board member, and operator in biotechnology ventures spanning small molecule therapeutics, biologics, and vaccine development, and serves as fund manager at the Harrington Discovery Institute.
JS
Jakub SimonChief Medical Officer
Investors · 1
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $215.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2010 | $297.3K |
| Environmental Protection Agency (EPA) | Phase II | 2005 | $225K |
| Environmental Protection Agency (EPA) | Phase II | 2005 | $224.7K |
| Environmental Protection Agency (EPA) | Phase I | 2004 | $69.9K |
| Environmental Protection Agency (EPA) | Phase I | 2004 | $69.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does BlueWillow Biologics do?
- BlueWillow Biologics develops an intranasal vaccine delivery platform using novel oil-in-water emulsion technology to address pandemic preparedness, infectious diseases, and food allergies. The company is a clinical-stage biotech firm with proprietary technology originally discovered at the University of Michigan.
- Who are BlueWillow Biologics's investors?
- BlueWillow Biologics's investors include Michigan Capital Network.
- Where is BlueWillow Biologics headquartered?
- BlueWillow Biologics is headquartered in Ann Arbor, US.